Evidence map›Paper›PMID 30987626›Full record

ArticleBMC cancer2019

Glucocorticoid-dependent expression of IAP participates in the protection against TNF-mediated cytotoxicity in MCF7 cells.

Irma B Mitre-Aguilar, Tonatiuh Barrios-Garcia, Victor M Ruiz-Lopez, Alberto J Cabrera-Quintero, Nancy R Mejia-Dominguez, Jose L Ventura-Gallegos, Daniel Moreno-Mitre, Alejandro Aranda-Gutierrez, Janini Mejia-Rangel, Alma R Escalona-Guzman and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. The Role of Glucocorticoids in Breast Cancer Therapy.Current oncology (Toronto, Ont.) · 2022
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Irma B Mitre-AguilarDepartamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico.ORCID http://orcid.org/0000-0001-6955-9003
Tonatiuh Barrios-GarciaPrograma de Investigacion en Cancer de Mama, IIBO, UNAM, 04510, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0003-1336-4658
Victor M Ruiz-LopezDepartamento de Biologia Molecular, Instituto Nacional de Enfermedades Respiratorias (INER), 14080, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0003-0440-2093
Alberto J Cabrera-QuinteroDepartamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico.ORCID http://orcid.org/0000-0001-5160-6836
Nancy R Mejia-DominguezRed de Apoyo a la Investigacion-Coordinacion de la Investigacion Cientifica (RAI-CIC), UNAM, 14080, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0002-5788-4586
Jose L Ventura-GallegosDepartamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico.ORCID http://orcid.org/0000-0002-3370-0949
Daniel Moreno-MitreUnidad de Bioquimica, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ), 14080, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0001-8474-1778
Alejandro Aranda-GutierrezUnidad de Bioquimica, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ), 14080, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0002-7325-8569
Janini Mejia-RangelDepartamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico.ORCID http://orcid.org/0000-0001-5368-9081
Alma R Escalona-GuzmanDepartamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico.ORCID http://orcid.org/0000-0003-3611-2824
Yanin Chavarri-GuerraDepartamento de Hemato-Oncologia, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, 14080, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0003-0792-1817
Alfonso Leon-Del-RioPrograma de Investigacion en Cancer de Mama, IIBO, UNAM, 04510, Mexico, CDMX, Mexico.ORCID http://orcid.org/0000-0001-7683-5109
Alejandro Zentella-DehesaDepartamento de Medicina Genomica y Toxicologia Ambiental, Instituto de Investigaciones Biomedicas (IIBO), Universidad Nacional Autonoma de Mexico (UNAM), 04510 Ciudad de Mexico (CDMX), Mexico, Mexico. azentell@iibiomedicas.unam.mx.ORCID http://orcid.org/0000-0002-5595-1466
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInstituto Nacional de Cancerología · MXInstituto Nacional de Enfermedades Respiratorias · MX

Funding

CONACYT 172558CONACYT 256725
6 · The paper itself

Abstract

backgroundGlucocorticoid receptor (GR) activation has been associated with breast cancer cell survival in vitro. Glucocorticoid (GC)-dependent protection against tumor necrosis factor (TNF)-induced cell death has been well characterized in MCF7 luminal A breast cancer cells. The GR activates a variety of protective mechanisms, such as inhibitors of apoptosis proteins (IAPs). However, the relative contribution of the GR-dependent expression of IAPs in the protection of cell death has not, to our knowledge, been evaluated.

methodsMCF7 cells were used for all experiments. GR was activated with cortisol (CORT) or dexamethasone (DEX) and inhibited with mifepristone (RU486). Cell viability was determined in real-time with the xCELLigence™ RTCA System and at specific endpoints using crystal violet stain. The mRNA levels of the eight members of the IAP family were measured by qRT-PCR. The protein levels of GR, PR, ERα, HER2, PARP1, c-IAP1 and XIAP were evaluated by Western blot analysis. The knockdown of c-IAP1 and XIAP was accomplished via transient transfection with specific siRNAs. GR activation was verified by a gene reporter assay. Via the cBioportal interphase we queried the mRNA levels of GR and IAPs in breast cancer tumors.

resultsRU486 significantly inhibited the anti-cytotoxic effect of both GCs. PARP1 processing was diminished in the presence of both GCs. The combined treatments of GCs + TNF increased the relative mRNA levels of Survivin>c-IAP1 > NAIP>Apollon>XIAP>Ts-IAP > ML-IAP > c-IAP2. Additionally, GR mRNA content increased with the combined treatments of GCs + TNF. Sustained levels of the proteins c-IAP1 and XIAP were observed after 48 h of the combined treatments with GCs + TNF. With c-IAP1 and XIAP gene silencing, the GC-mediated protection was diminished. In the breast tumor samples, the GR mRNA was coexpressed with Apollon and XIAP with a Pearson coefficient greater than 0.3.

conclusionsThe effect of GCs against TNF-mediated cytotoxicity involves increased mRNA expression and sustained protein levels of c-IAP1 and XIAP. The antagonist effects of RU486 and the qRT-PCR results also suggest the role of the GR in this process. This finding may have clinical implications because the GR and IAPs are expressed in breast tumor samples.

Indexed as

ApoptosisBiomarkersCell DeathCell Line, TumorCell SurvivalGene Expression Regulation, NeoplasticGenes, ReporterGlucocorticoidsHumansInhibitor of Apoptosis ProteinsMCF-7 CellsRNA, MessengerTumor Necrosis Factor-alphaBiomarkersGlucocorticoidsInhibitor of Apoptosis ProteinsRNA, MessengerTumor Necrosis Factor-alphaCell deathGlucocorticoid receptorGlucocorticoidsInhibitor of apoptosis proteinsMCF7 cellsTumor necrosis factor

Identifiers

PMID30987626
PMCPMC6466787
OpenAlexW2946538231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.